Rethinking child treatments

Developing evidence-based treatments - specifically for children

Releases

Releases

18. November, 2022

Third quarter report Q3-2022

Cessatech today releases its results for the period 1 July – 30 September 2022....

Read more

Releases

14. November, 2022

Successful outcome of Rights issue

The results of the rights issue announced on October 19, 2022 for which the...

Read more

Releases

19. October, 2022

DKK 18.3 million capital raise through a 80% guarantee

DKK 18.3 MILLION CAPITAL RAISE THROUGH A 80% GUARANTEED RIGHTS ISSUE TO FINANCE PIVOTAL...

Read more

Releases

23. September, 2022

Successful outcome of pharmacokinetic trial in children of lead candidate

Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001...

Read more

Releases

5. September, 2022

First patient dosed in pivotal trial of lead product candidate

First patient has been dosed in pivotal trial of lead candidate CT001 The pivotal...

Read more

Facts about Children

Facts

15. March, 2022

Off-label use of medication in children continue to be the rule rather than the exception…

A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...

Read more

Facts

3. March, 2022

Physical restraint of children in 79% of Scandinavian emergency departments

Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...

Read more

Facts

2. February, 2021

Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner

Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...

Read more

Facts

8. September, 2020

Behov for større sikkerhed omkring medicin til børn og unge i Danmark

Kun 30% af markedsførte lægemidler i EU er godkendt til børn, og kun 50%...

Read more

Facts

31. August, 2020

DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem

Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...

Read more

Experience

Proven track-record within drug development and product launches, in Europe, US and Asia.

The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.

Team
Lead Asset

CT001 – Nasal spray

Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.

See details

Stay up to date!

Subscribe and get notified on Cessatech's latest news.